Abstract Number: LPB0097
Meeting: ISTH 2021 Congress
Theme: Arterial Thromboembolism » Atherosclerosis
Background: Microvesicles(MVs) are small vesicles deriving from all cell type. MVs seems to be one of the procoagulant determinants in type 2 diabetes(T2DM).
Aims: To assess the effects of chronic low dose aspirin(ASA) on levels of total MVs and specific subtypes, such as platelet(PMV), endothelial(EMV), leucocytes(LMV) in DM and non-DM patients in the 24-hour interval between 2 witnessed ASA administrations.
Methods: We enrolled 59 patients with and 41 without T2DM, at cardiovascular risk, on chronic low-dose ASA treatment. The kinetics of platelet cyclooxygenase-1 recovery(COX-1) was characterized by measuring serum TXB2 after 10 and 24 hours after a witnessed ASA administration. Nine healthy subjects were enrolled to verify the number of MVs on circadian measurements. Each subject signed written informed consent. Protocol was approved.
Results: Total MVs levels and the number of CD45+ LMV were reduced at T10 as compared to T24 within both DM(p <0.001 and p=0.009, respectively) and noDM patients(p <0.001 and p=0.034) and in the two groups(p <0.001 both).The CD41a+PMVs and CD31+EMV did not show differences between T10 and T24 in DM and in non-DM patients, whereas reduced levels at T10 vs. T24 were observed for Annex-positive CD41a+ PMVs . In healthy subjects, nodifference in the levels of total MV, PMV and EMV was observed between T10 and T24, over 24 h between two ASA administrations.
Levels of Total Microvescicles, and Platelet derived Microvescicles Annex positive in patients with and without diabetes after 10 and 24 hours after a witnessed aspirin administration
Conclusions: In ASA-treated subjects, daily administration may inhibit the release of total MV and annexin-positive, phosphatydilserine -exposing, PMVduring the 24-hour dosing interval. After excluding a circadian variation in MV levels, mirrored by the stability of the phenotype in healthy subjects, the inhibition after 10 hours since a witnessed ASA administration suggests that COX-1 dependent mechanisms may be involved in this inhibition. With the limits of a cross-sectional study, our findings suggest a previously unappreciated effect of ASA.
To cite this abstract in AMA style:
Simeone P, Liani R, Tripaldi R, Ciotti S, Lanuti P, Marchisio M, Miscia S, Santilli F. Role of Low-dose Aspirin on the Release of Circulating Microvesicles in Patients at Cardiovascular Risk with and without Type 2 Diabetes [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 1). https://abstracts.isth.org/abstract/role-of-low-dose-aspirin-on-the-release-of-circulating-microvesicles-in-patients-at-cardiovascular-risk-with-and-without-type-2-diabetes/. Accessed September 24, 2021.« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/role-of-low-dose-aspirin-on-the-release-of-circulating-microvesicles-in-patients-at-cardiovascular-risk-with-and-without-type-2-diabetes/